Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
949results about "Screening process" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods and compositions for selecting siRNA of improved functionality
InactiveUS20050255487A1Improve efficiencyGood curative effectOrganic active ingredientsGenetic material ingredientsGene silencingSilencing gene
Owner:THERMO FISHER SCIENTIFIC INC
Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
InactiveUS20080113351A1High RNA interference effectLittle riskOrganic active ingredientsNervous disorderBase JNucleotide
The present invention provides a polynucleotide that not only has a high RNA interference effect on its target gene, but also has a very small risk of causing RNA interference against a gene unrelated to the target gene. A sequence segment conforming to the following rules (a) to (d) is searched from the base sequences of a target gene for RNA interference and, based on the search results, a polynucleotide capable of causing RNAi is designed, synthesized, etc.:(a) The 3′ end base is adenine, thymine, or uracil,(b) The 5′ end base is guanine or cytosine,(c) A 7-base sequence from the 3′ end is rich in one or more types of bases selected from the group consisting of adenine, thymine, and uracil, and(d) The number of bases is within a range that allows RNA interference to occur without causing cytotoxicity.
Owner:ALPHAGEN
Functional and hyperfunctional siRNA
ActiveUS20050246794A1Improve efficiencyGood curative effectOrganic active ingredientsGenetic material ingredientsSilent geneGene silencing
Owner:THERMO FISHER SCIENTIFIC INC
Single Cell Nucleic Acid Detection and Analysis
ActiveUS20140155274A1High amplification efficiencyEasy to detectMicrobiological testing/measurementScreening processNucleic acid detectionNucleic acid sequencing
Methods and compositions for digital profiling of nucleic acid sequences present in a sample are provided.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Micrornas and uses thereof
Described herein are novel polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
Owner:ROSETTA GENOMICS
Dilation introducer for orthopedic surgery
InactiveUS20050256525A1Lowering chance damageInvasive surgical procedureOrganic active ingredientsGenetic material ingredientsDilatorBone tissue
The dilation introducer has a locked assembled configuration for placement of the dilation introducer against a patient's tissue to be treated, and an unlocked, collapsed configuration for dilating the patient's soft tissue down to tissue to be treated. Dilator tubes are successively released and advanced to progressively expand the patient's soft tissue down to the bone tissue to be treated. The dilator tubes and a guide insert may include spikes for engaging bone tissue. The dilation introducer may include a light emitter disposed in a dilator tube. A telescoping expander sleeve is also provided.
Owner:INTERVENTIONAL SPINE
Methods and compositions involving mirna and mirna inhibitor molecules
InactiveUS20080050744A1Effective amountReduce percentageAntibacterial agentsOrganic active ingredientsBiologyCellular functions
The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and / or miRNA inhibitors are used in library screening assays.
Owner:ASURAGEN
Single cell nucleic acid detection and analysis
ActiveUS9260753B2Improve dynamic rangeReduce or eliminate the amplification biasMicrobiological testing/measurementScreening processNucleic acid detectionNucleic acid sequencing
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
MicroRna-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers
ActiveUS20080306006A1Inhibiting tumorigenesisPrevent proliferationOrganic active ingredientsPeptide/protein ingredientsMicroRNASolid cancer
The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provide methods of identifying inhibitors of tumorigenesis.
Owner:THE OHIO STATE UNIV RES FOUND
Modified polynucleotides for reducing off-target effects in RNA interference
InactiveUS7595387B2Minimizing off-target effectSugar derivativesHydrolasesSense strandPolynucleotide
Owner:MERCK & CO INC +1
Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
InactiveUS20070099196A1Solve low usageSugar derivativesMicrobiological testing/measurementGeneticsTarget mrna
The invention relates relates to ribonucleic acids and oligonucleotide probes useful for detection and analysis of microRNAs and their target mRNAs, as well as small interfering RNAs (siRNAs).
Owner:EXIQON AS
Methods and systems for identifying naturally occurring antisense transcripts and methods, kits and arrays utilizing same
InactiveUS20050009771A1Microbiological testing/measurementGenetic material ingredientsNucleotidePolynucleotide
Owner:COMPUGEN
Methods and systems for identifying naturally occurring antisense transcripts and methods, kits and arrays utilizing same
InactiveUS20030228618A1Microbiological testing/measurementGenetic material ingredientsNucleotidePolynucleotide
A method of identifying putative naturally occurring antisense transcripts is provided. The method is effected by (a) computationally aligning a first database including sense-oriented polynucleotide sequences with a second database including expressed polynucleotide sequences; and (b) identifying expressed polynucleotide sequences from the second database being capable of forming a duplex with at least one sense-oriented polynucleotide sequence of the first database, thereby identifying putative naturally occurring antisense transcripts.
Owner:COMPUGEN
Ketol-acid reductoisomerase using nadh
Methods for the evolution of NADPH specific ketol-acid reductoisomerase enzymes to acquire NADH specificity are provided. Specific mutant ketol-acid reductoisomerase enzymes isolated from Pseudomonas that have undergone co-factor switching to utilize NADH are described.
Owner:GEVO INC
Modified polynucleotides for reducing off-target effects in RNA interference
ActiveUS20050223427A1Easy to retouchBroaden applicationSugar derivativesHydrolasesGene silencingPolynucleotide
Methods and compositions for performing RNA interference with decreased off-target effects are provided The methods and compositions permit effective and efficient applications of RNA interference to applications such as diagnostics and therapeutics through the use of modifications to the siRNA. Uniquely modified siRNAs have been developed that reduce off-target effects incurred in gene-silencing. The modifications comprise 2′-O-alkyl or mismatch modification(s) at specific positions on the sense and / or antisense strands.
Owner:MERCK & CO INC +1
Methods and Compositions Involving microRNA
InactiveUS20080026951A1Improve efficiencyAvoid dye-quenchingMicrobiological testing/measurementLibrary screeningMicroRNABiochemistry
Owner:ASURAGEN
Microrna as ligands and target molecules
InactiveUS20050142581A1Improve bindingIncreased binding affinityMicrobiological testing/measurementScreening processMicroRNAMass spectrometry
The present invention provides methods for the identification of target molecules that bind to ligands, particularly microRNA ligands and mimics thereof and / or microRNA target molecules and mimics thereof, with as little as millimolar (mM) affinity using mass spectrometry. The methods may be used to determine the mode of binding interaction between two or more of these target molecules to the ligand as well as their relative affinities. Also provided are methods for designing compounds having greater affinity to a ligand by identifying two or more target molecules using mass spectrometry methods of the invention and linking the target molecules together to form a novel compound.
Owner:IONIS PHARMA INC
Control of gene expression
Owner:COMMONWEALTH SCI & IND RES ORG
Micrornas and uses thereof
Described herein are polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
Owner:ROSETTA GENOMICS
Signal activated RNA interference
ActiveUS20090234109A1Eliminate steric hindranceInhibits the degradation of the blocking sequenceSugar derivativesScreening processHomopolynucleotideDicer
The invention provides compositions and methods for signal activated RNA interference (saRNAi), preferably in vivo. The invention provides polynucleotides that switches between an inactive form and an active form upon covalent or non-covalent interaction with one or more specific chemical signals, such as disease-specific mRNA, miRNA, or other cellular RNA products with sequences that characterize diseased states of the cell. The interaction between the subject polynucleotides and the signals is preferably mediated by hybridization, which exposes, facilitates the formation, and / or allows the formation of a substrate that can be processed by proteins of the RNAi pathway (such as Dicer). The input and output of multiple different polynucleotides of the invention can form an in vivo signaling network. In addition, the multiple input signals can be integrated to modulate the activity of the subject polynucleotides.
Owner:CALIFORNIA INST OF TECH
Multicomponent nucleic acid enzymes and methods for their use
ActiveUS20070231810A1DetectableGuaranteed detection effectSugar derivativesMicrobiological testing/measurementBiologyOligonucleotide
The present invention relates to Multicomponent Nucleic Acid Enzymes (MNAzymes) and methods for their use. MNAzymes comprise two or more oligonucleotide components which self-assemble in the presence of one or more MNAzyme assembly facilitator molecules to form a catalytically active structure. Compositions for making MNAzymes, and collections of MNAzymes are provided. Also provided are methods for using MNAzymes for the detection, identification and / or quantification of one or more targets. The methods can be practiced in solution-based assays or in assays where one or more reaction components are attached to a support structure. The methods allow for multiplexing the MNAzyme detection to detect multiple targets in a single reaction. Also provided are kits for making the compositions, and for practicing the methods provided herein.
Owner:SPEEDX
Methods and compositions for selective RNAi mediated inhibition of gene expression in mammal cells
InactiveUS20050026286A1Reducing sequenceMicroorganismsMicrobiological testing/measurementMammalMammalian cell
RNAi arrays and methods for using the same are provided. The subject arrays are characterized by having two or more distinct RNAi agents. The arrays find use in methods where cells are contacted with the arrays and the activity of the RNAi agents is determined by evaluating the contacted cells. The subject arrays and methods find use in a variety of applications, such as high throughput loss of function genomic applications.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
InactiveUS20070065840A1Strong specificityHigh sensitivitySugar derivativesMicrobiological testing/measurementTarget mrnaAllele
The invention relates to ribonucleic acids and oligonucleotide probes useful for detection and analysis of microRNAs and their target mRNAs, as well as small interfering RNAs (siRNAs). The invention furthermore relates to oligonucleotide probes for detection and analysis of other non-coding RNAs, mRNAs, mRNA splice variants, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g. alterations associated with human disease, such as cancer.
Owner:EXIQON AS
MicroRNA biomarkers for human breast and lung cancer
The present invention relates to novel molecular markers for diagnosis and classification of human breast cancer and lung cancer.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE +1
Biosensors for detecting macromolecules and other analytes
InactiveUS20060110739A1Bioreactor/fermenter combinationsBiological substance pretreatmentsAnalyteBiosensor
Owner:SAINT LOUIS UNIVERSITY
Use of the microRNA miR-1 for the treatment, prevention, and diagnosis of cardiac conditions
InactiveUS20090005336A1High expressionOrganic active ingredientsSugar derivativesDiseaseCoronary artery disease
Among >300 miRNAs known to date, miR-1 is considered muscle-specific. Here we show that that miR-1 overexpressed in individuals with coronary artery disease, and when overexpressed, it exacerbated arrhythmogenesis in both infarcted and normal hearts of rats whereas elimination of miR-1 by its antisense inhibitor relieved it. MiR-1 rendered slowed conduction and depolarized membrane by post-transcriptionally repressing KCNJ2 and GJA1 genes, likely accounting for its arrhythmogenic potential. Thus, miR-1 may have important pathophysiological functions in heart, being a novel antiarrhythmic target useful in the treatment and prevention of various cardiac pathologies.
Owner:WANG ZHIGUO
METHODS OF IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERING RNA(siRNA)
InactiveUS20090053140A1Inhibition effectOrganic active ingredientsMicrobiological testing/measurementMemory formationTreated animal
The present invention relates to a method of identifying a gene or gene product associated with transcription dependent memory formation in an animal comprising the steps of: (a) administering to said animal sufficient small interfering RNA (siRNA) specific for the gene to inhibit gene function; (b) training said animal under conditions sufficient to induce transcription dependent memory formation in a normal untreated animal; and (c) determining the level of transcription dependent memory formation induced by the training of the treated animal. The present invention provides methods of using small interfering PNAs (siRNA) in hippocampus to identify genes and gene product whose inhibition affects contextual and temporal long-term (LTM) memory, but not short-term memory (STM).
Owner:HELICON THERAPEUTICS
Synthetic lethal screen using RNA interference
InactiveUS20050181385A1Modulate activityFew or no effectsSugar derivativesMicrobiological testing/measurementDiseaseDNA damage
The invention provides a method for identifying one or more genes in a cell of a cell type which interact with, e.g., modulate the effect of, an agent, e.g., a drug. For example, an identified gene may confer resistance or sensitivity to a drug, i.e., reduces or enhances the effect of the drug. The invention also provides STK6 and TPX2 as a gene that exhibits synthetic lethal interactions with KSP encoding a kinesin-like motor protein, and methods and compositions for treatment of diseases, e.g., cancers, by modulating the expression of STK6 or TPX2 gene and / or the activity of STK6 or TPX2 gene product. The invention also provides genes involved in cellular response to DNA damage, and their therapeutic uses.
Owner:MERCK SHARP & DOHME CORP
MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CLL) and Uses Thereof
InactiveUS20120283310A1Improve impactReduce expressionOrganic active ingredientsGenetic material ingredientsDiseaseChronic lymphocytic leukemia
Methods and compositions for the diagnosis, prognosis and / or treatment of leukemia associated diseases are disclosed.
Owner:THE OHIO STATE UNIV RES FOUND
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com